HIV Disease Coverage Forecast and Market Analysis to 2027

Figure 1: The author's assessment summary of key marketed and pipeline drugs for HIV
Figure 2: HIV total market value across the US and five major EU markets, by country, 2018-27
Figure 3: HIV total market value across the US and five major EU markets, by class, 2018-27
Figure 4: HIV sales in the US, 2018–27
Figure 5: HIV sales in the five major EU markets, by country, 2018–27
Figure 6: Sales of Biktarvy compared to INSTI-based STRs and injectables, by product, 2018–27
Figure 7: The author's HIV forecast methodology
Figure 8: Price sources and calculations, by country
Figure 9: The author's drug assessment summary of Atripla for HIV
Figure 10: The author's drug assessment summary of Atripla for HIV
Figure 11: Atripla sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 12: The author's drug assessment summary of Biktarvy for HIV
Figure 13: The author's drug assessment summary of Biktarvy for HIV
Figure 14: Biktarvy sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 15: The author's drug assessment summary of Complera for HIV
Figure 16: The author's drug assessment summary of Complera for HIV
Figure 17: Complera sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 18: The author's drug assessment summary of Delstrigo for HIV
Figure 19: The author's drug assessment summary of Delstrigo for HIV
Figure 20: Delstrigo sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 21: The author's drug assessment summary of Descovy for HIV
Figure 22: The author's drug assessment summary of Descovy for HIV
Figure 23: Descovy sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 24: The author's drug assessment summary of Dovato for HIV
Figure 25: The author's drug assessment summary of Dovato for HIV
Figure 26: Dovato sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 27: The author's drug assessment summary of Genvoya for HIV
Figure 28: The author's drug assessment summary of Genvoya for HIV
Figure 29: Genvoya sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 30: The author's drug assessment summary of Isentress for HIV
Figure 31: The author's drug assessment summary of Isentress for HIV
Figure 32: Isentress sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 33: The author's drug assessment summary of Juluca for HIV
Figure 34: The author's drug assessment summary of Juluca for HIV
Figure 35: Juluca sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 36: The author's drug assessment summary of Odefsey for HIV
Figure 37: The author's drug assessment summary of Odefsey for HIV
Figure 38: Odefsey sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 39: The author's drug assessment summary of Prezista franchise for HIV
Figure 40: The author's drug assessment summary of Prezista franchise for HIV
Figure 41: Prezista sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 42: Prezcobix sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 43: The author's drug assessment summary of Reyataz franchise for HIV
Figure 44: The author's drug assessment summary of Reyataz franchise for HIV
Figure 45: Reyataz sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 46: Evotaz sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 47: The author's drug assessment summary of Stribild for HIV
Figure 48: The author's drug assessment summary of Stribild for HIV
Figure 49: Stribild sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 50: The author's drug assessment summary of Symtuza for HIV
Figure 51: The author's drug assessment summary of Symtuza for HIV
Figure 52: Symtuza sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 53: The author's drug assessment summary of Tivicay for HIV
Figure 54: The author's drug assessment summary of Tivicay for HIV
Figure 55: Tivicay sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 56: The author's drug assessment summary of Triumeq for HIV
Figure 57: The author's drug assessment summary of Triumeq for HIV
Figure 58: Triumeq sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 59: The author's drug assessment summary of Trogarzo for HIV
Figure 60: The author's drug assessment summary of Trogarzo for HIV
Figure 61: Trogarzo sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 62: The author's drug assessment summary of Truvada for HIV
Figure 63: The author's drug assessment summary of Truvada for HIV
Figure 64: Truvada sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 65: The author's drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 66: The author's drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 67: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 68: The author's drug assessment summary of fostemsavir for HIV
Figure 69: The author's drug assessment summary of fostemsavir for HIV
Figure 70: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 71: The author's drug assessment summary of leronlimab for HIV
Figure 72: The author's drug assessment summary of leronlimab for HIV
Figure 73: Leronlimab sales for HIV in the US, 2018–27
Figure 74: Percentage of HIV prevalent population who are diagnosed and undiagnosed in the US and five major EU markets, by country
Figure 75: Percentage of the HIV-diagnosed population under physician care in the US and five major EU markets, by country
Figure 76: Breakdown of pharmacologically treated HIV patients in the US and five major EU markets, by line of therapy and country
Figure 77: Percentage of respondents in the US and five major EU markets who agree with initiating treatment in all patients, by country
Figure 78: Treatment status of HIV patients under physician care in the US and five major EU markets, by country
Figure 79: Top five brands used for the treatment of first-line HIV patients, by country
Figure 80: Top five regimens used for the treatment of first-line HIV patients, by country
Figure 81: Top five regimens used for the treatment of second-line HIV patients, by country
Figure 82: Top five brands used for the treatment of second-line HIV patients, by country
Figure 83: Top five regimens used for the treatment of third-line HIV patients, by country
Figure 84: Top five brands used for the treatment of third-line HIV patients, by country
Figure 85: Top five regimens used for the treatment of fourth-line and beyond HIV patients, by country
Figure 86: Top five brands used for the treatment of fourth-line and beyond HIV patients, by country
Figure 87: Relative importance of unmet needs in HIV treatment in the US and five major EU markets, by country
Figure 88: Physician views on potential adherence impact of breaking up FDCs in HIV in the US and five major EU markets, by country
Figure 89: Extent of physician comfort with breaking up FDCs to prescribe separate generic components in HIV in the US and five major EU markets, by country
Figure 90: Physician views on whether cost savings justify the breaking up of FDCs in HIV in the US and five major EU markets, by country
Figure 91: The author's drug assessment summary of Atripla for HIV
Figure 92: The author's drug assessment summary of Atripla for HIV
Figure 93: Atripla sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 94: The author's drug assessment summary of Biktarvy for HIV
Figure 95: The author's drug assessment summary of Biktarvy for HIV
Figure 96: Biktarvy sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 97: The author's drug assessment summary of Complera for HIV
Figure 98: The author's drug assessment summary of Complera for HIV
Figure 99: Complera sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 100: The author's drug assessment summary of Delstrigo for HIV
Figure 101: The author's drug assessment summary of Delstrigo for HIV
Figure 102: Delstrigo sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 103: The author's drug assessment summary of Descovy for HIV
Figure 104: The author's drug assessment summary of Descovy for HIV
Figure 105: Descovy sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 106: The author's drug assessment summary of Dovato for HIV
Figure 107: The author's drug assessment summary of Dovato for HIV
Figure 108: Dovato sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 109: The author's drug assessment summary of Genvoya for HIV
Figure 110: The author's drug assessment summary of Genvoya for HIV
Figure 111: Genvoya sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 112: The author's drug assessment summary of Isentress for HIV
Figure 113: The author's drug assessment summary of Isentress for HIV
Figure 114: Isentress sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 115: The author's drug assessment summary of Juluca for HIV
Figure 116: The author's drug assessment summary of Juluca for HIV
Figure 117: Juluca sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 118: The author's drug assessment summary of Odefsey for HIV
Figure 119: The author's drug assessment summary of Odefsey for HIV
Figure 120: Odefsey sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 121: The author's drug assessment summary of Prezista franchise for HIV
Figure 122: The author's drug assessment summary of Prezista franchise for HIV
Figure 123: Prezista sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 124: Prezcobix sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 125: The author's drug assessment summary of Reyataz franchise for HIV
Figure 126: The author's drug assessment summary of Reyataz franchise for HIV
Figure 127: Reyataz sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 128: Evotaz sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 129: The author's drug assessment summary of Stribild for HIV
Figure 130: The author's drug assessment summary of Stribild for HIV
Figure 131: Stribild sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 132: The author's drug assessment summary of Symtuza for HIV
Figure 133: The author's drug assessment summary of Symtuza for HIV
Figure 134: Symtuza sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 135: The author's drug assessment summary of Tivicay for HIV
Figure 136: The author's drug assessment summary of Tivicay for HIV
Figure 137: Tivicay sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 138: The author's drug assessment summary of Triumeq for HIV
Figure 139: The author's drug assessment summary of Triumeq for HIV
Figure 140: Triumeq sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 141: The author's drug assessment summary of Trogarzo for HIV
Figure 142: The author's drug assessment summary of Trogarzo for HIV
Figure 143: Trogarzo sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 144: The author's drug assessment summary of Truvada for HIV
Figure 145: The author's drug assessment summary of Truvada for HIV
Figure 146: Truvada sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 147: The author's drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 148: The author's drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 149: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 150: The author's drug assessment summary of fostemsavir for HIV
Figure 151: The author's drug assessment summary of fostemsavir for HIV
Figure 152: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2018–27
Figure 153: The author's drug assessment summary of leronlimab for HIV
Figure 154: The author's drug assessment summary of leronlimab for HIV
Figure 155: Leronlimab sales for HIV in the US, 2018–27

Table 1: Recent events incorporated into the HIV forecast
Table 2: HIV – current and future market dynamics analysis
Table 3: HIV – current and future forecast trends
Table 4: Exchange rates used for calculating prices
Table 5: Infectious disease specialists surveyed for the HIV primary research study, 2017
Table 6: Atripla drug profile
Table 7: Approval history of Atripla for HIV in the US and five major EU markets
Table 8: Late-phase trials of Atripla for HIV
Table 9: Atripla for HIV – SWOT analysis
Table 10: Biktarvy drug profile
Table 11: Approval history of Biktarvy for HIV in the US, Japan, and five major EU markets
Table 12: Late-phase trials of Biktarvy for HIV
Table 13: Biktarvy for HIV – SWOT analysis
Table 14: Complera drug profile
Table 15: Approval history of Complera for HIV in the US, Japan, and five major EU markets
Table 16: Late-phase trials of Complera for HIV
Table 17: Complera for HIV – SWOT analysis
Table 18: Delstrigo drug profile
Table 19: Approval history of Delstrigo for HIV in the US and five major EU markets
Table 20: Late-phase trials of Delstrigo for HIV
Table 21: Delstrigo for HIV – SWOT analysis
Table 22: Descovy drug profile
Table 23: Approval history of Descovy for HIV in the US, Japan, and five major EU markets
Table 24: Late-phase trials of Descovy for HIV
Table 25: Descovy for HIV – SWOT analysis
Table 26: Dovato drug profile
Table 27: Approval history of Dovato for HIV in the US
Table 28: Late-phase trials of Dovato for HIV
Table 29: Dovato for HIV – SWOT analysis
Table 30: Genvoya drug profile
Table 31: Approval history of Genvoya for HIV in the US, Japan, and five major EU markets
Table 32: Late-phase trials of Genvoya for HIV
Table 33: Genvoya for HIV – SWOT analysis
Table 34: Isentress drug profile
Table 35: Approval history of Isentress for HIV in the US, Japan, and five major EU markets
Table 36: Late-phase trials of Isentress for HIV
Table 37: Isentress for HIV – SWOT analysis
Table 38: Juluca drug profile
Table 39: Approval history of Juluca for HIV in the US, Japan, and five major EU markets
Table 40: Late-phase trials of Juluca for HIV
Table 41: Juluca for HIV – SWOT analysis
Table 42: Odefsey drug profile
Table 43: Approval history of Odefsey for HIV in the US and five major EU markets
Table 44: Late-phase trials of Odefsey for HIV
Table 45: Odefsey for HIV – SWOT analysis
Table 46: Prezista drug profile
Table 47: Prezcobix drug profile
Table 48: Approval history of Prezista for HIV in the US, Japan, and five major EU markets
Table 49: Late-phase trials of Prezista for HIV
Table 50: Approval history of Prezcobix for HIV in the US, Japan, and five major EU markets
Table 51: Late-phase trials of Prezcobix for HIV
Table 52: Prezista franchise for HIV – SWOT analysis
Table 53: Reyataz drug profile
Table 54: Evotaz drug profile
Table 55: Approval history of Reyataz for HIV in the US, Japan, and five major EU markets
Table 56: Late-phase trials of Reyataz for HIV
Table 57: Approval history of Evotaz for HIV in the US and five major EU markets
Table 58: Late-phase trials of Evotaz for HIV
Table 59: Reyataz franchise for HIV – SWOT analysis
Table 60: Stribild drug profile
Table 61: Approval history of Stribild for HIV in the US, Japan, and five major EU markets
Table 62: Late-phase trials of Stribild for HIV
Table 63: Stribild for HIV – SWOT analysis
Table 64: Symtuza drug profile
Table 65: Approval history of Symtuza for HIV in the US and five major EU markets
Table 66: Late-phase trials of Symtuza for HIV
Table 67: Symtuza for HIV – SWOT analysis
Table 68: Tivicay drug profile
Table 69: Approval history of Tivicay for HIV in the US, Japan, and five major EU markets
Table 70: Late-phase trials of Tivicay for HIV
Table 71: Tivicay for HIV – SWOT analysis
Table 72: Triumeq drug profile
Table 73: Approval history of Triumeq for HIV in the US, Japan, and five major EU markets
Table 74: Late-phase trials of Triumeq for HIV
Table 75: Triumeq for HIV – SWOT analysis
Table 76: Trogarzo drug profile
Table 77: Approval history of Trogarzo for HIV in the US
Table 78: Late-phase trials of Trogarzo for HIV
Table 79: Trogarzo for HIV – SWOT analysis
Table 80: Truvada drug profile
Table 81: Approval history of Truvada for HIV in the US, Japan, and five major EU markets
Table 82: Late-phase trials of Truvada for HIV
Table 83: Truvada for HIV – SWOT analysis
Table 84: Cabotegravir/rilpivirine drug profile
Table 85: Late-phase trials of cabotegravir/rilpivirine for HIV
Table 86: Cabotegravir/rilpivirine for HIV – SWOT analysis
Table 87: Fostemsavir drug profile
Table 88: Late-phase trials of fostemsavir for HIV
Table 89: Fostemsavir for HIV – SWOT analysis
Table 90: Leronlimab drug profile
Table 91: Late-phase trials of leronlimab for HIV
Table 92: Leronlimab for HIV – SWOT analysis
Table 93: Infectious disease specialists surveyed for the HIV primary research study, 2017
Table 94: Therapies discussed in the HIV key opinion leader primary research study, 2017
Table 95: HIV total infections, new infections, and AIDS-attributable deaths, by region, 2016
Table 96: New HIV diagnoses in the US and five major EU markets, by transmission route, 2016
Table 97: Per-act HIV transmission risk, by transmission route
Table 98: CDC classification system for HIV-infected adults and adolescents
Table 99: Symptomatic conditions included in CDC HIV classification system clinical categories
Table 100: WHO clinical staging of HIV/AIDS for adults and adolescents
Table 101: Treatments available for HIV across the US and five major EU markets
Table 102: Summary of "recommended" treatment options in HHS and EACS treatment guidelines
Table 103: HIV prevalence, infections, and AIDS-attributable deaths in 2017, by region
Table 104: Sources used for the epidemiological analysis of HIV in the US, Japan, and five major EU markets, by country
Table 105: Data sources used to describe the diagnosed prevalent HIV population, by country
Table 106: Data sources used to segment diagnosed incident HIV cases by AIDS at diagnosis, by country
Table 107: Data sources used to segment diagnosed incident HIV cases by transmission category, by country
Table 108: Diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2018–28
Table 109: Incident cases of HIV diagnosed at AIDS stage, in adults, in the US, Japan, and five major EU markets, by country, 2018
Table 110: Number and proportion of incident HIV cases, by transmission route, and country, 2018
Table 111: Total prevalent cases of HIV in the US, Japan, and five major EU markets, by country, 2018–28
Table 112: Diagnosed and undiagnosed prevalent HIV cases, by country, 2018
Table 113: Co-morbid bone and renal impairments in adult diagnosed prevalent HIV cases, by country, 2018
Table 114: Profiled key marketed drugs for HIV
Table 115: Atripla drug profile
Table 116: Approval history of Atripla for HIV in the US and five major EU markets
Table 117: Late-phase trials of Atripla for HIV
Table 118: Atripla for HIV – SWOT analysis
Table 119: Biktarvy drug profile
Table 120: Approval history of Biktarvy for HIV in the US, Japan, and five major EU markets
Table 121: Late-phase trials of Biktarvy for HIV
Table 122: Biktarvy for HIV – SWOT analysis
Table 123: Complera drug profile
Table 124: Approval history of Complera for HIV in the US, Japan, and five major EU markets
Table 125: Late-phase trials of Complera for HIV
Table 126: Complera for HIV – SWOT analysis
Table 127: Delstrigo drug profile
Table 128: Approval history of Delstrigo for HIV in the US and five major EU markets
Table 129: Late-phase trials of Delstrigo for HIV
Table 130: Delstrigo for HIV – SWOT analysis
Table 131: Descovy drug profile
Table 132: Approval history of Descovy for HIV in the US, Japan, and five major EU markets
Table 133: Late-phase trials of Descovy for HIV
Table 134: Descovy for HIV – SWOT analysis
Table 135: Dovato drug profile
Table 136: Approval history of Dovato for HIV in the US
Table 137: Late-phase trials of Dovato for HIV
Table 138: Dovato for HIV – SWOT analysis
Table 139: Genvoya drug profile
Table 140: Approval history of Genvoya for HIV in the US, Japan, and five major EU markets
Table 141: Late-phase trials of Genvoya for HIV
Table 142: Genvoya for HIV – SWOT analysis
Table 143: Isentress drug profile
Table 144: Approval history of Isentress for HIV in the US, Japan, and five major EU markets
Table 145: Late-phase trials of Isentress for HIV
Table 146: Isentress for HIV – SWOT analysis
Table 147: Juluca drug profile
Table 148: Approval history of Juluca for HIV in the US, Japan, and five major EU markets
Table 149: Late-phase trials of Juluca for HIV
Table 150: Juluca for HIV – SWOT analysis
Table 151: Odefsey drug profile
Table 152: Approval history of Odefsey for HIV in the US and five major EU markets
Table 153: Late-phase trials of Odefsey for HIV
Table 154: Odefsey for HIV – SWOT analysis
Table 155: Prezista drug profile
Table 156: Prezcobix drug profile
Table 157: Approval history of Prezista for HIV in the US, Japan, and five major EU markets
Table 158: Late-phase trials of Prezista for HIV
Table 159: Approval history of Prezcobix for HIV in the US, Japan, and five major EU markets
Table 160: Late-phase trials of Prezcobix for HIV
Table 161: Prezista franchise for HIV – SWOT analysis
Table 162: Reyataz drug profile
Table 163: Evotaz drug profile
Table 164: Approval history of Reyataz for HIV in the US, Japan, and five major EU markets
Table 165: Late-phase trials of Reyataz for HIV
Table 166: Approval history of Evotaz for HIV in the US and five major EU markets
Table 167: Late-phase trials of Evotaz for HIV
Table 168: Reyataz franchise for HIV – SWOT analysis
Table 169: Stribild drug profile
Table 170: Approval history of Stribild for HIV in the US, Japan, and five major EU markets
Table 171: Late-phase trials of Stribild for HIV
Table 172: Stribild for HIV – SWOT analysis
Table 173: Symtuza drug profile
Table 174: Approval history of Symtuza for HIV in the US and five major EU markets
Table 175: Late-phase trials of Symtuza for HIV
Table 176: Symtuza for HIV – SWOT analysis
Table 177: Tivicay drug profile
Table 178: Approval history of Tivicay for HIV in the US, Japan, and five major EU markets
Table 179: Late-phase trials of Tivicay for HIV
Table 180: Tivicay for HIV – SWOT analysis
Table 181: Triumeq drug profile
Table 182: Approval history of Triumeq for HIV in the US, Japan, and five major EU markets
Table 183: Late-phase trials of Triumeq for HIV
Table 184: Triumeq for HIV – SWOT analysis
Table 185: Trogarzo drug profile
Table 186: Approval history of Trogarzo for HIV in the US
Table 187: Late-phase trials of Trogarzo for HIV
Table 188: Trogarzo for HIV – SWOT analysis
Table 189: Truvada drug profile
Table 190: Approval history of Truvada for HIV in the US, Japan, and five major EU markets
Table 191: Late-phase trials of Truvada for HIV
Table 192: Truvada for HIV – SWOT analysis
Table 193: Profiled pipeline products in development for HIV
Table 194: Cabotegravir/rilpivirine drug profile
Table 195: Late-phase trials of cabotegravir/rilpivirine for HIV
Table 196: Cabotegravir/rilpivirine for HIV – SWOT analysis
Table 197: Fostemsavir drug profile
Table 198: Late-phase trials of fostemsavir for HIV
Table 199: Fostemsavir for HIV – SWOT analysis
Table 200: Leronlimab drug profile
Table 201: Late-phase trials of leronlimab for HIV
Table 202: Leronlimab for HIV – SWOT analysis